Avoiding Channel Lock-In During U.S. Market Entry

Early U.S. market entry requires commitment, but it should not require surrendering strategic flexibility. A manufacturer may initially depend on one distributor, sales representative, logistics provider, or commercialization partner because sales volumes are uncertain and internal resources are limited. The arrangement should nevertheless allow the manufacturer to adapt as products, customers, and geographic priorities develop.

Contract duration is a central consideration. A multi-year agreement may appear to provide stability, but it can become restrictive if the partner underperforms, changes priorities, or proves unsuitable for later growth. Renewal terms, notice periods, automatic extensions, and termination rights should therefore be reviewed together. A contract that is nominally terminable may still create practical lock-in if termination triggers fees, inventory purchases, minimum-payment obligations, or repayment of setup costs.

Exclusivity requires particular caution. Broad exclusivity by product, customer type, geography, or sales channel can prevent the manufacturer from adding specialized distributors, pursuing direct sales, supporting key opinion leaders, serving federal accounts, or testing direct-to-patient and veterinary opportunities. Any exclusivity should be clearly defined, supported by measurable performance obligations, and capable of narrowing or ending if agreed results are not achieved.

Minimum purchase commitments can demonstrate partner engagement, but they should be realistic and distinguished from forecasts, sales targets, and non-binding business plans. The agreement should specify whether failure permits termination, loss of exclusivity, damages, or another remedy.

Control of commercial information is equally important. Some distributors provide sales reporting only at ZIP-code level rather than identifying the purchasing healthcare professional or institution. That may be inadequate in dense medical districts, such as the Texas Medical Center in Houston, where many healthcare providers may operate within the same ZIP code. Aggregate reporting can prevent the manufacturer from knowing which accounts are purchasing, where adoption is developing, or whether apparent market penetration is concentrated within a few institutions.

Limited reporting may also constrain post-market activities. Depending on the manufacturer’s EU post-market clinical follow-up plan, more granular information may be needed to identify relevant users or sites, collect clinical experience, obtain user feedback, or investigate use patterns. Distributor sales reports do not themselves constitute PMCF data, but inadequate account-level visibility can make planned PMCF activities harder to organize and document.

MDD Options’ hybrid distribution model is designed to preserve this optionality. Because the manufacturer or its representative generates the sale, the manufacturer retains direct visibility of the healthcare professional, institution, transaction, and market-development activity rather than relying solely on summarized distributor reports. Open-ended arrangements, short notice periods, transparent records, and coexistence with other channels allow partners to be added, supplemented, or replaced as the market evolves. MDD Options can also help assess channel agreements and transition risks where another commercial structure is being considered.